SM03, a non-depleting anti-CD22 antibody, modulates B cell activation and immune crosstalk to attenuate autoimmunity

Kin Lok Wong, Lung Hei Cheng, Cheuk Ling Chung, Pui Lam Ng, Shaik Abdullah Nawabjan, Ka Kiu Luk, Shui On Leung, Muthu Iswarya Gandhi Sethuraman, Wing Tung Tsoi, Billy Kwok Chong Chow
Journal of Translational Autoimmunity · Elsevier · DOI: 10.2139/ssrn.6451790

Abstract

Objective To evaluate the disease-modifying potential of SM03, a novel humanized anti-CD22 monoclonal antibody, for B cell-mediated autoimmune diseases by investigating its unique mechanism of suppressing B cell dysregulation in autoimmune milieu. Methods SM03's mechanism was assessed in-vitro using functional assays on stimulated human PBMC from healthy donors and patients with Systemic Lupus Erythematosus/Sjögren's Syndrome. The efficacy of SM03 to attenuate autoimmunity was then evaluated in-vivo in a humanized pristane-induced Systemic Lupus Erythematosus mouse model as well as a preventive collagen-induced Rheumatoid Arthritis model in cynomolgus monkeys. Disease-specific biomarkers, histopathology, and immune cell phenotypes were analysed. Results SM03 attenuated T cell–dependent B cell activation by reducing class-switched B cells, plasma-blast differentiation, and pro-inflammatory cytokine production in B cell lines, healthy and disease PBMCs, without inducing B cell depletion. In the SLE model, SM03 suppressed key disease manifestations (splenomegaly, anti-dsDNA, proteinuria, glomerular deposits) and reduced activated T cells, matching rituximab's efficacy without broad B cell depletion. In the arthritis model, SM03 dose-dependently suppressed joint scores, cartilage damage, synovial hyperplasia, anti-collagen II antibodies, and IL-6. Conclusion By enhancing CD22's inhibitory signalling to disrupt autoreactive B-T cell interactions, SM03 functions as a disease-modifying therapy that attenuates dysregulation of lymphocytes in autoimmunity. This non-depleting mechanism supports its translational potential for SLE and RA and implicates its broader utility for other B cell-driven autoimmune diseases.

Read at publisher →

Similar articles